HR Execs on the Move

PharmaLinkFHI Inc

www.pharmalinkfhi.com

 
PharmaLinkFHI (PharmaLink) is the first full-service Clinical Research Organization (CRO) to integrate clinical and technological expertise in managing Phase I-IV clinical trials online in real time. Biopharmaceutical and medical device organizations
  • Number of Employees: 250-1000
  • Annual Revenue: $100-250 Million

Executives

Name Title Contact Details

Similar Companies

Cingulate Therapeutics

Cingulate Therapeutics, LLC (CTx) is a privately held biopharmaceutical company focused on the development of new products for the treatment of central nervous system and neurobiological disorders.

ABS Corporation

ABS Corporation is a Omaha, NE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sanford House

Sanford House in Grand Rapids, Michigan is a drug and alcohol rehab and recovery center. We offer residential and non-residential treatment options for both men and women in Michigan and across the country. Our Johns Street location provides detox for ...

Y Prime

The process that we follow for all projects is simple: we translate real-world experiences into expert advice. Whether this is through consulting or software applications, we align our entire organization to help you solve the specifics of challenges faced. When organizations engage with Y Prime, they have a dedicated support team that never changes. The people you work with from Day 1 will be there until completion of your project – no “knowledge transfers,” or redundant personnel required.  

Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates to address large market opportunities, initially in ophthalmic conditions, where there are limited treatment alternatives. It is advancing its pipeline to address several diseases across therapeutic categories including eye care, dermatology, and other diseases with high, unmet needs. Its lead product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of Demodex blepharitis.